Jamil M. Beg

Jamil joined SV in 2024 as a Partner on the Biotech team

Jamil is a life science investor and company builder focused on advancing break-through science into transformational medicines for patients. Prior to joining SV, Jamil was a Partner at 5AM Ventures, a US-based life sciences venture fund, where he was responsible for investing in biotech companies across therapeutic areas and modalities and ranging from company creation to later, clinical-stage companies.

Over his career, Jamil has been involved in over twenty private financings, seven public offerings, and three M&A transactions. He has operated in six venture-backed startups and contributed to the advancement of multiple FDA approved products. Select investments and operating roles include Akouos (NASDAQ: AKUS, acquired by Eli Lilly), Aprea (NASDAQ: APRE), Kinaset Therapeutics, Nido Biosciences, RallyBio (NASDAQ: RLYB), Sage Therapeutics (NASDAQ: SAGE), Transave Inhalation Therapeutics (merged with Insmed) and several stealth biotech startups. Jamil brings a wealth of entrepreneurial and operational expertise from his time building companies like Sage Therapeutics and Nido Biosciences.

Outside of SV, Jamil enjoys being in the great outdoors, whether backpacking, fishing, or scuba diving in the summer or snowboarding in the winter. He also enjoys cooking new dishes and learning about wine.

Academic credentials

BSE, Bioengineering, University of Pennsylvania
Master of Biotechnology, University of Pennsylvania
MBA, Healthcare Management, Entrepreneurial Management, The Wharton School of the University of Pennsylvania (where he was recipient of the Henry J. Kaiser Family Foundation Merit Award)